Application of wedelolactone in preparing drug for resisting ulcerative colitis

A technology for ulcerative colitis and wecarolide, which is applied to the application field of werethrin in the preparation of anti-ulcerative colitis medicines, and achieves the effects of wide practical value, clear pharmacological activity, and improvement of symptoms of colitis.

Inactive Publication Date: 2015-11-11
CHINA PHARM UNIV
View PDF7 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

At present, there is no literature report that wedelolide has the efficacy of treating

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of wedelolactone in preparing drug for resisting ulcerative colitis
  • Application of wedelolactone in preparing drug for resisting ulcerative colitis
  • Application of wedelolactone in preparing drug for resisting ulcerative colitis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0036] Example 1 In vivo pharmacological effect study of wedelolide reducing ulcerative colitis

[0037] 1.1 Experimental materials

[0038] 1.1.1 Experimental animals and drugs

[0039] Clean grade C57BL / 6 mice, female, 18-22g, were purchased from the Comparative Medicine Center of Yangzhou University (certificate number: NO.201502346). The experimental animals were housed in separate cages, the bedding was changed every 2 days, and the adaptive feeding was carried out for 7 days. Water and food were free to drink during the experiment. The temperature of the feeding environment is 22±2°C, the relative humidity is 60%, and the cycle of 12 hours of light and 12 hours of darkness is carried out every day.

[0040] After drying and pulverizing the Chinese herbal medicine Eclipta chinensis, reflux extraction with 80% ethanol to obtain the extract, concentration under reduced pressure and sequential extraction with equal amounts of petroleum ether and ethyl acetate, the ethyl ac...

Embodiment 2

[0074] Example Two Wedelolide reduces the pro-inflammatory effect of IL-1B on Caco-2

[0075] Caco-2 cells are a cell line derived from human colorectal adenocarcinoma epithelium. When the growth reaches fusion, they can spontaneously differentiate and form polarity, showing the morphological structure and functional characteristics of mature intestinal epithelial cells. They are ideal for studying colonic epithelial protein expression. ideal cell for its function [1] . IL-8 in the intestinal mucosa is a protein secreted by giant cells, epithelial cells, and fibroblasts. The level of IL-8 in the lesion mucosa increases, and the elevated level is related to the degree of intestinal inflammation [2] . In order to observe the anti-ulcerative colitis mechanism of wedelide, we firstly use MTT experiment to determine the safety range of wedelide on Caco-2 cells; then pretreat Caco- 2 cells, to detect changes in the level of inflammation, to explore its possible mechanism, and to ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to an application of Chinese traditional herb monomer wedelolactone as a drug for treating ulcerative colitis. According to the application, wedelolactone is obtained from Chinese traditional herb material eclipta, and the structure of wedelolactone is determined according to spectrum data. Through intragastric administration of wedelolactone, the body weight change of a model mouse is obviously changed, the length of the colon is increased, the inflammation level of the colon is obviously hanged, the NO content reflecting the inflammation degree of the colon is reduced, the activity of myeloperoxidase (MPO) in the colon tissue is reduced, release of inflammatory factors IL-8 of Caco-2 cells excited byIL-1beta is inhibited in vitro. The results of in-vivo and in-vitro experiments show that wedelolactone under certain dosage can obviously inhibit release of the inflammatory factors of the colon tissue, so that the acute ulcerative colitis of the mouse caused by dextran sulphate sodium salt (DSS) can be obviously improved, and therefore, wedelolactone has a novel application as a drug for treating or improving ulcerative colitis.

Description

technical field [0001] The invention relates to a new use of wedelolide, a monomer substance, as a medicine for treating inflammatory bowel disease. Background technique [0002] Ulcerative colitis (UC) is a chronic intestinal inflammatory disease of unknown etiology and easy to relapse. The lesions mainly occur in the colon and its submucosa, involving the rectum, and gradually spread to part or the whole colon. Inflammation and ulcers are the main features of UC [1，2] . The clinical manifestations are abdominal pain, persistent diarrhea and bloody stool, fever, abdominal distension and other symptoms, which seriously affect people's quality of life. In European and American countries, the incidence of UC exceeds that of Asian countries, and the incidence of UC in my country is also showing an upward trend. [3] . Drugs for clinical UC treatment are mainly divided into the following categories: glucocorticoids, aminosalicylic acids, immunosuppressants, antibiotics, and s...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/37A61P1/04
Inventor 张朝凤丁美玲魏文成刘倩玉
Owner CHINA PHARM UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap